Evidence map›Paper›PMID 39730423›Full record

ArticleScientific reports2024

Quantitative IgG response to SARS-CoV-2 membrane protein in infected individuals strongly correlates with lung injury.

Giovanni Faggioni, Filippo Moramarco, Emiliana Luciano, Riccardo De Santis, Alessandra Amoroso, Giancarlo Petralito, Filippo Molinari, Paolo Grosso, Orr Rozov, Diego Morelli and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Giovanni FaggioniDefence Institute for Biomedical Sciences, 00184, Rome, Italy. giovanni.faggioni@gmail.com.
Filippo MoramarcoDefence Institute for Biomedical Sciences, 00184, Rome, Italy.
Emiliana LucianoDefence Institute for Biomedical Sciences, 00184, Rome, Italy.
Riccardo De SantisDefence Institute for Biomedical Sciences, 00184, Rome, Italy.
Alessandra AmorosoDefence Institute for Biomedical Sciences, 00184, Rome, Italy.
Giancarlo PetralitoDefence Institute for Biomedical Sciences, 00184, Rome, Italy.
Filippo MolinariDefence Institute for Biomedical Sciences, 00184, Rome, Italy.
Paolo GrossoItalian Department of Defence, 00184, Rome, Italy.
Orr RozovFood and Agriculture Organization, 00153, Rome, Italy.
Diego MorelliArmy Medical Centre, 00184, Rome, Italy.
Daniele CarboneDefence Institute for Biomedical Sciences, 00184, Rome, Italy.
Florigio ListaDefence Institute for Biomedical Sciences, 00184, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical manifestations of SARS-CoV-2 infection may range from asymptomatic or minor conditions to severe and life-threatening outcomes. The respiratory system is a principal target of the virus and in the majority of cases of severe disease, an acute form of pneumonia develops. Despite concerted global efforts to elucidate the pathogenic mechanisms of COVID-19, the progression of the infection leading to pulmonary damage remains poorly understood. The present study aimed to analyse the immunological profile of subjects with a previous SARS-CoV-2 infection and predisposition to lung injury. The results showed a strong correlation between IgG anti-membrane antibodies and lung injury.

Indexed as

Antibodies, ViralCOVID-19Immunoglobulin GSARS-CoV-2AdultAgedCoronavirus M ProteinsFemaleHumansLung InjuryMaleMiddle AgedAntibodies, ViralCoronavirus M ProteinsImmunoglobulin Gmembrane protein, SARS-CoV-2COVID-19Lung injurySARS-CoV-2 membrane protein

Identifiers

PMID39730423
PMCPMC11681004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.